BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

Broad-spectrum coronavirus protease inhibitors  A Wichita State University, University of Iowa and Kansas State University team reported in a Science Translational Medicine article the generation of a series of inhibitors of the protease 3CLpro from...
BioCentury | Aug 7, 2020

Guardant’s liquid biopsy approval paves the way for broader adoption of solid tumor profiling

FDA’s approval of a liquid biopsy test from Guardant that produces a comprehensive tumor mutational profile may trigger broader adoption of the tumor screening technology to better match patients to targeted therapies. FDA approved Guardant360...
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

CymaBay plans to re-start pivotal trial  Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) rose $1.33 (37%) to $4.88 Monday after 78.2% of primary biliary cholangitis (PBC) patients on its seladelpar met the primary composite outcome of...
BioCentury | Jul 31, 2020

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21. Polyphor...
BioCentury | Jul 27, 2020

AZ goes early for its latest $1B ADC deal with Daiichi

With the success of Enhertu as the template, AstraZeneca is putting at least a further $1 billion on the line for a much earlier stage ADC in a new deal with Daiichi Sankyo. AstraZeneca plc...
BioCentury | Jul 24, 2020

Olema aims to deploy $54M round to carve its niche in breast cancer

Olema’s plans for its oral selective estrogen receptor degrader attracted a crossover-laden syndicate to the San Francisco company’s $54 million series B round. Olema plans to take the therapy, which is administered daily, into a...
BioCentury | Jul 23, 2020

EQRx brings in next-in-class CDK4/6, EGFR inhibitors in bid for radically cheaper drugs

The first disclosed deals for Alexis Borisy’s EQRx provide a glimpse of the targets and economics of its low-cost approach to drug development. The company, which launched in January with $200 million, is using a...
BioCentury | Jul 23, 2020
Emerging Company Profile

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Jul 14, 2020

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
Items per page:
1 - 10 of 3512